Effectiveness of diethylcarbamazine in treating loiasis acquired by expatriate visitors to endemic regions: long-term follow-up

J Infect Dis. 1994 Mar;169(3):604-10. doi: 10.1093/infdis/169.3.604.

Abstract

Although successful treatment of loiasis with diethylcarbamazine (DEC) has been reported, little is known about the long-term success rate of therapy or the predisposing factors for treatment failure. To address these questions, 32 patients were followed 2-15 years (median, 4.5) after DEC treatment; all had acquired infection while expatriate visitors to endemic areas of Africa. Using a strict definition of successful treatment, 12 (38%) appeared to be cured after one course of therapy and 5(16%) after two courses. Of the remaining 15 patients, 3 continued to be symptomatic despite more than four courses of treatment. Although 12 of the 17 patients who relapsed did so within 1 year of treatment, several had relatively long asymptomatic periods (2-8 years). There was no predictive difference in clinical or laboratory parameters (including eosinophilia and specific filarial serology) between patients requiring one or more courses of therapy.

MeSH terms

  • Diethylcarbamazine / therapeutic use*
  • Follow-Up Studies
  • Humans
  • Loiasis / drug therapy*
  • Loiasis / epidemiology
  • Loiasis / immunology
  • Loiasis / transmission
  • Recurrence
  • Travel

Substances

  • Diethylcarbamazine